PubMed Health⌕ Search

Biomedical subjects

T Månsson

Publications and source records attributed to T Månsson.

15 recordsLinked to original sources
PubMed1999

Treatment with paclitaxel 1-h infusion and carboplatin of patients with advanced non-small-cell lung cancer: a phase II multicentre trial. Joint Lung Cancer Study Group.

The primary aim of this phase II study was to determine the response rate of a combination of paclitaxel and carboplatin in advanced non-small cell lung cancer (NSCLC) in a multicentre setting. The secondary aim was to determine time to progression (TTP), 1-year survival rate and toxicity. 65 patients were treated and all of them were included in the follow up for survival and toxicity. 60 patients were followed for response rate and time to progression. 55% were stage IV patients and 45% stage IIIB patients. The treatment consisted of paclitaxel 200 mg/m2 given as a 1-h i.v. infusion and carboplatin given as a 30 min i.v. infusion and the latter was dosed by using the Calvert formula at an area under the concentration time curve (AUC) of 5. The glomerular filtration rate (GFR) was determined by iohexol clearance and was not calculated from the serum creatinine level. The chemotherapy courses were given every third week with a maximum number of six or eight courses for patients who responded late. As premedication we used 8 mg betamethasone 40 min prior to infusion and then 10 min later clemastin and cimetidine. One complete response and 18 partial responses were seen giving a response rate of 29%. 40% of the patients progressed during the treatment and 28% had stable disease. The median TTP was 22 weeks. At a minimum follow up of 1 year, the 1-year survival rate was 38% and the median survival rate was 41 weeks. Haematological toxicity was mild with no grade 4 leucopenia and only seven patients (11%) had grade 3 leucopenia. There was no grade 4 toxicity. Grade 3 toxicity was seen as myalgia 5%, allergic reaction 3% and peripheral neuropathy 6%. 15% of the patients had a dose reduction due to neurotoxicity. The haematological toxicity was much milder than we expected, probably because of more exact determination of the GFR. This trial confirms the results of earlier reported trials of the efficacy and the ease of the regimen as an out-patient treatment option in advanced NSCLC. The main problem with this treatment is peripheral neuropathy.

Adult↗
PubMed1991

Efficacy of enprofylline in acute airway obstruction.

The efficacy and safety of different regimens of intravenously administered enprofylline, an anti-asthma xanthine, were evaluated in a randomized open study, including 155 patients with acute exacerbation of obstructive lung disease. The regimen 2.5 mg/kg i.v. over 10 min was canceled after seven patients had been included, due to two cases of hypotensive/vasovagal reactions. The regimens 2.0 mg/kg/20 min and 2.5 mg/kg/20 min were significantly more effective with regard to bronchodilation than 2.0 mg/kg/10 min (PEF increase +35%, +30% and +17% respectively). Nausea and headache were the most common side effects (16-33% and 23-33% of the patients respectively on different regimens) with the lowest frequency on 2.0 mg/kg/20 min. Four additional hypotensive reactions occurred; one on each 2.0 mg/kg regimen and two on 2.5 mg/kg/20 min. The regimen 2.0 mg/kg20 min was found to be the most favourable with regard to efficacy and side effects. Enprofylline i.v. was found to be an effective bronchodilating treatment of acute airway obstruction but the frequency of side effects has to be considered.

Acute Disease↗
PubMed1988

Familial occurrence of eccrine tumours in a family with ectodermal dysplasia.

In two brothers and their sister, ectodermal defects including hypodontia, onychodystrophia, trichodysplasia and palmoplantar keratosis were observed. In addition to the ectodermal dysplasia a diffuse palmoplantar eccrine hyperplasia was noted as well as tumours and cysts of eccrine origin. This seems to be the first report of familial occurrence of eccrine tumours.

Adenocarcinoma↗
PubMed1988

Treatment of malignant pleural effusion with doxycycline.

Pleurodesis for effective control of malignant pleural effusion can be induced with various methods and agents. In 18 patients with histologically or cytologically proven malignant pleural effusion, 500 mg doxycycline hydrochloride diluted in 30 ml of saline was instilled into the emptied pleural space. Tube drainage was performed using suction or gravity. More than one doxycycline instillation was required in 13 cases. Serial chest radiography showed the response to be complete in 11 of the 18 patients and partial in four, while three did not respond. There was no difference between the results obtained with the two drainage systems. In all of the complete responders who died there was no sign of reaccumulated pleural effusion at terminal admission, despite clinical evidence of systemic tumor progression. Three patients--all with breast carcinoma--are alive after 5-27 months, two as complete responders and one as partial responder. The most common side effect was pleuritic pain, defined as significant if narcotic analgesics were required. A moderate febrile reaction appeared in four patients during the first 24 hours post-instillation. The study showed doxycycline to be an effective sclerosing agent for inducing pleurodesis, with acceptable adverse effects.

Aged↗
PubMed1987

Vasculitis simulating eczematous dermatitis due to C2 deficiency.

In a patient with total C2 deficiency and repeated respiratory infections a papulovesicular rash showed to be due to leukocytoclastic vasculitis. The patient's brother also had a total deficiency of C2 but no clinical symptoms. HLA-investigation in both him and the proband showed the genotype commonly reported in cases with homozygous C2 deficiency. Their heterozygous mother and sister had slightly decreased C2 levels.

Adult↗
PubMed1986

Subtotal C4 deficiency and SLE-like disease.

Extremely low C4 values were found in a 65-year-old man with relapsing arthritis and skin lesions of many years duration of the scalp, face, hands and feet together with painful ulcerations of the toes and fingers. The discovery was made during an exacerbation, but the deficiency of C4 persisted in repeated controls after remission. The clinical findings in connection with these low C4 values are in congruence with the diagnosis of inherited deficiency of C4.

Aged↗
PubMed1985

Recurrent cutaneous jellyfish eruptions without envenomation.

Three patients exhibiting recurrent cutaneous eruptions induced by contact with jellyfish tentacles are presented. The recurrent eruptions appeared several days after the primary exposure without contact with any offending coelenterate. The principal species involved include Pelagia noctiluca, Physalia physalis and probably Lychnorhiza lucerna. These three cases, combined with an earlier similar report of recurrent lesions induced by Physalia physalis suggest that this phenomenon may be widespread. In two of the three cases, the secondary eruption was more severe than that occurring after the primary envenomation.

Adolescent↗
PubMed1983

A randomized trial comparing cadexomer iodine and standard treatment in the out-patient management of chronic venous ulcers.

Ninety-three patients with treatment-resistant venous ulcers were included in a multicentre randomized trial to compare cadexomer iodine and the standard treatment used in each centre combined with compression bandages, in healing venous ulcers. The mean duration of ulcers before the trial was more than 2 years. With standard treatment the mean ulcer size increased slightly during the 6-week trial whereas with cadexomer iodine the ulcer size was significantly reduced. Cadexomer iodine was more effective than standard treatment for reduction of pain, removal of pus and debris, removal of exudate, stimulation of granulation and reduction of surrounding erythema. Bacterial infection of ulcers increased or did not change during treatment with the standard therapy whereas cadexomer iodine significantly reduced infection with Staphylococcus aureus, Pseudomonas aeruginosa and other pathogenic organisms. A correlation was seen between the time taken to reduce or eliminate infection with Staphylococcus aureus and rate of ulcer healing. Four patients complained of transient pain in the ulcer after application of the cadexomer iodine. It is concluded that cadexomer iodine increased the rate of healing of infected chronic venous ulcers.

Administration, Topical↗
PubMed1981

Antibody responses in man after single or repeated treatment with intramuscular ampicillin.

Antibody responses to the penicilloyl moiety were recorded in patients treated intramuscularly with ampicillin for respiratory infections. For practical reasons this was performed at two clinics. At each clinic, two commercially available ampicillin preparations were used in a single-blind, randomised study. One of the preparations at each clinic was of high-grade purity and the other was slightly contaminated, according to a radioimmunoassay. There was the same heterogeneity in the patient material between the two clinics. The results showed a slight but significant (p less than 0.001) increase in IgM penicilloyl antibodies in the group of patients treated with the pure penicillin but not in those treated with the contaminated penicillin. When the patients in the two studies were analysed jointly, the increase in IgM antibodies was significantly greater (p less than 0.05) in the group treated with pure penicillin than in that treated with impure penicillin. The difference in antibody formation between the patient groups treated with pure or contamined ampicillin at each clinic was not significant, however. An immunological activity of the impurities suppressing the IgM antibody response is suggested.

Adult↗